BMS 823778
Alternative Names: BMS823778Latest Information Update: 05 Nov 2023
At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperglycaemics; Antihyperlipidaemics
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia; Type 2 diabetes mellitus
Most Recent Events
- 23 Aug 2013 Bristol-Myers Squibb terminates a phase II trial for Hypertension (in overweight and obese patients) early in recruitment in the US, the EU and Latin America (NCT01602367)
- 15 Jul 2013 Bristol-Myers Squibb withdraws a phase II trial for Artherosclerosis prior to enrolment (NCT01666704)
- 28 Aug 2012 Bristol-Myers Squibb plans a phase II trial for Artherosclerosis in USA (NCT01666704)